Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer.
about
Monoclonal antibodies.C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancerReal-time PCR complements immunohistochemistry in the determination of HER-2/neu status in breast cancerMechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome ItAn Experimental Analysis of the Molecular Effects of Trastuzumab (Herceptin) and Fulvestrant (Falsodex), as Single Agents or in Combination, on Human HR+/HER2+ Breast Cancer Cell Lines and Mouse Tumor XenograftsProtective effects of different antioxidants against cadmium induced oxidative damage in rat testis and prostate tissuesBiological and clinical significance of HER2 overexpression in breast cancer.Comparison of multiplex ligation dependent probe amplification to immunohistochemistry for assessing HER-2/neu amplification in invasive breast cancer.COX-2 and PPARgamma expression are potential markers of recurrence risk in mammary duct carcinoma in-situc-erbB2 expression predicts tamoxifen efficacy in breast cancer patients.HER-2/neu as a predictive marker of response to breast cancer therapy.Molecular prognostic markers in breast cancer.Role of HER2 gene overexpression in breast carcinoma.Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer.Function of RasGRP3 in the formation and progression of human breast cancerBombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenes.Prognostic and Predictive Factors for Breast Cancer.Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer.Testing for HER2 in Breast Cancer: A Continuing Evolution.Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from transgenic mice.Anti-human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer.ZD1839: targeting the epidermal growth factor receptor in cancer therapy.Prognostic and predictive value of HER2/neu oncogene in breast cancer.HER4 in breast cancer: comparison of antibodies against intra- and extra-cellular domains of HER4Expression of SRC-1, AIB1, and PEA3 in HER2 mediated endocrine resistant breast cancer; a predictive role for SRC-1.Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer.IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest in breast carcinoma.Therapeutic potential of tyrosine kinase inhibitors in breast cancer.Radioimmunolocalisation in breast cancer using the gene product of c-erbB2 as the target antigencDNA transfection followed by the isolation of a MCF-7 breast cell line resistant to tamoxifen in vitro and in vivo.Elevated levels of members of the STAT family of transcription factors in breast carcinoma nuclear extracts.Neoplastic progression of breast epithelial cells--a molecular analysis.Prognostic factors for breast cancer and their use in the clinical setting.Variation of hormonal receptor, pS2, c-erbB-2 and GSTpi contents in breast carcinomas under tamoxifen: a study of 74 cases.pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patientsActivated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapyAnti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer.ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer.Analysis of factors affecting endocrine therapy resistance in breast cancer.Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer.
P2860
Q24535231-9BC4F6BD-C0AE-4D10-832F-2C6999E67BE0Q24795406-63CA9A73-ECAC-4A8D-A068-84F32F9EB689Q25257296-12FD2F7A-DE52-4CA0-8038-1F3F41ABBCD0Q26752780-08A6E3D1-BB4F-4E8F-A392-6F5438336CF2Q28468447-33A92445-28CD-4986-9A37-17340F3E37FEQ28568420-44D04874-6F65-4B6E-A913-D04A1BFDFFF8Q31950781-5C2CB24F-C2D4-4ACD-809E-3053C905D383Q33253893-7B315DD3-467F-45D9-9F9D-5F1B03274A64Q33317621-7C122F69-90BD-45C3-99AB-24742A3FE3C7Q33538427-3889F457-CE29-4C68-8AD1-058FFD959A68Q33538428-ED433EE6-4C4B-4EB4-9439-4F5BE54E7F8BQ33538447-4D3A9E29-2DB5-41D8-A757-A35A4E978F52Q33810080-9BD3897F-9CF6-424F-B38D-E35E6AB77144Q33917455-042DAD05-EC18-469F-8CCE-47A37B7420C2Q33960160-01431786-D598-4035-9136-66E02AEA8E85Q34020681-FB1660CD-4CA6-4A24-8E5E-0DB8D9B2BDAFQ34089296-DD8A42FE-57F4-4539-BC7E-34942D0C3CA5Q34255976-DB1E5923-D57F-4C7C-A622-AB2ABF633B54Q34424285-F5125D82-094C-44E7-BA76-8185B625992EQ34521619-47FDDF0F-C23C-478C-BCCA-038D262E0E02Q34548277-D4948EF6-F1DC-4B28-84DE-25E95A679506Q34660887-1984C328-0F95-4AD7-ACDD-904956DB2FBEQ34954864-6C56F2F2-7E31-4397-A125-5395AC1A3BC0Q35012797-9F76FA6B-F3D9-4764-87B7-DE7B645334B1Q35588055-C1E3FABD-4049-44FB-9234-BD605F7E8F7DQ35588592-009128A3-E9CB-42CE-9D2E-310F9B766B43Q35588768-CFE0676F-313D-4717-84B7-1EA324F6C13BQ35589209-07B694E0-A85B-4FBB-8A3C-A3AD5982747DQ35976545-6F9C5216-B685-44D3-9968-0049DCB8C4ECQ35977569-116BAE8B-1103-4549-AFBD-2C0FDF7FAAF7Q36080795-3942561F-2413-48F1-A376-F4C92D486CA1Q36114717-1E6F726B-DEC5-4038-AB6C-9D5DBA0846A6Q36118398-DAEE9175-7EC4-475F-AF0A-6605B0E65406Q36134697-8C0EDBD8-2898-454A-A03D-8394B49F9F15Q36141002-8B235F64-9B65-4BDA-87C3-59887E12DF4EQ36223407-49833108-B925-49E9-A4D3-ED2979490EE7Q36245510-1F5E5748-1D6F-4DCC-9DC8-705056DEB2F3Q36245537-2B761EC1-5549-444D-84E9-BC0CB7EF9B41Q36502389-43C0D762-C7D2-4453-9321-6A65C12F73E1Q36617556-98E160A8-706E-4E03-ACAC-16270C6DE992
P2860
Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Relationship between c-erbB-2 ...... apy in advanced breast cancer.
@ast
Relationship between c-erbB-2 ...... apy in advanced breast cancer.
@en
type
label
Relationship between c-erbB-2 ...... apy in advanced breast cancer.
@ast
Relationship between c-erbB-2 ...... apy in advanced breast cancer.
@en
prefLabel
Relationship between c-erbB-2 ...... apy in advanced breast cancer.
@ast
Relationship between c-erbB-2 ...... apy in advanced breast cancer.
@en
P2093
P2860
P356
P1476
Relationship between c-erbB-2 ...... apy in advanced breast cancer.
@en
P2093
Nicholson S
Sainsbury JR
P2860
P2888
P304
P356
10.1038/BJC.1992.22
P407
P577
1992-01-01T00:00:00Z